March 27 (Reuters) - Fresenius Kabi:
FRESENIUS KABI: REACHED A GLOBAL SETTLEMENT WITH AMGEN CONCERNING THEIR DENOSUMAB BIOSIMILARS
FRESENIUS KABI: LAUNCH OF CONEXXENCE & BOMYNTRA IN THE U.S. IN MID-2025 AND IN EUROPE LATER IN H2 OF 2025
Further company coverage: AMGN.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.